Moderna CEO: Anti-vaccine sentiment in the U.S. is rising, no intention to invest in new clinical trials
Moderna (MRNA.US) CEO Stephane Bancel stated that due to the increasing opposition from U.S. officials regarding vaccines, the company has no plans to invest in new late-stage vaccine clinical trials.
He pointed out that if they cannot enter the U.S. market, the investment will be difficult to recoup. At the same time, regulatory delays and the lack of support from U.S. health officials are significantly shrinking the potential market size.
After taking office, U.S. Health Secretary Robert F. Kennedy Jr. tightened the eligibility for COVID-19 vaccinations and questioned the vaccination arrangements and safety
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments